Psychopharmacology Today: Where are We and Where Do We Go From Here?
2010

Psychopharmacology Today: Where are We and Where Do We Go From Here?

Editorial

Author Information

Author(s): Thomas L. Schwartz

Primary Institution: SUNY Upstate Medical University

Hypothesis

What can we do as psychopharmacologists today, and tomorrow, to obtain better results despite using neurotransmitter pharmacodynamics that have been around since the 1950s?

Conclusion

We have made medicines safer and treated more patients, but continue to do an average job as far as outcomes are concerned with monotherapies.

Supporting Evidence

  • Psychopharmacologists have been using the same neurotransmitter systems since the 1950s.
  • Current medications are safer but do not show improved efficacy.
  • Only one third of patients achieve remission with monotherapy.

Takeaway

Doctors have been using the same types of medicines for mental health since the 1950s, and while they are safer now, they aren't necessarily better at helping people feel better.

Limitations

The study discusses the limitations of current psychopharmacological practices and the lack of new effective medications.

Digital Object Identifier (DOI)

10.4103/0973-1229.58816

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication